


1. A compound represented by the following formula (I) or a pharmaceutically acceptable acid addition salt thereof:



R<sub>1</sub> is a chlorine atom, a bromine atom, a trifluoromethyl group, an ethyl group, a trifluoromethoxy group, a methoxy group substituted with a phenyl group, a methoxy group substituted with a C<sub>3-8</sub> cycloalkyl group, an ethoxy group optionally substituted with 1 to 3 fluorine atoms, or C<sub>3-8</sub> cycloalkyloxy group,

R<sub>2</sub> is a fluorine atom, a chlorine atom, a methyl group optionally substituted with 2 to 3 fluorine atoms, a methoxy group optionally substituted with 1 to 3 fluorine atoms, or an ethoxy group optionally substituted with 1 to 3 fluorine atoms,

R<sub>4</sub> is a fluorine atom or a methyl group optionally substituted with 1 to 3 fluorine atoms, or

R<sub>1</sub> is a hydrogen atom, a halogen atom, a C<sub>1-6</sub> alkyl group optionally substituted with 1 to 3 fluorine atoms, a C<sub>1-6</sub> alkoxy group optionally substituted with 1 to 3 substituents selected from a fluorine atom and a C<sub>3-8</sub> cycloalkyl group, a C<sub>3-8</sub> cycloalkyloxy group, or a 4- to 6-membered heterocycloalkyloxy group,

R<sub>2</sub> is a hydrogen atom, a cyano group, a halogen atom, a C<sub>1-6</sub> alkyl group optionally substituted with 1 to 3 substituents selected from a fluorine atom and a hydroxyl group, or a C<sub>1-6</sub> alkoxy group optionally substituted with 1 to 3 substituents selected from a fluorine atom, a C<sub>3-8</sub> cycloalkyl group and a 4- to 6-membered heterocycloalkyl group,

R<sub>3</sub> is a hydrogen atom or a C<sub>1-6</sub> alkyl group, and

R<sub>4</sub> is a C<sub>1-6</sub> alkyl group optionally substituted with 1 to 3 substituents selected from a fluorine atom and a hydroxyl group, or a C<sub>1-6</sub> alkoxy group.

2. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 1, wherein

R is a C<sub>1-6</sub> alkyl group optionally substituted with 1 to 3 fluorine atoms,

R<sub>1</sub> is a hydrogen atom, a halogen atom, a C<sub>1-6</sub> alkyl group optionally substituted with 1 to 3 fluorine atoms, a C<sub>1-6</sub> alkoxy group optionally substituted with 1 to 3 substituents selected from a fluorine atom and a C<sub>3-8</sub> cycloalkyl group, a C<sub>3-8</sub> cycloalkyloxy group, or a 4- to 6-membered heterocycloalkyloxy group,

R<sub>2</sub> is a hydrogen atom, a cyano group, a halogen atom, a C<sub>1-6</sub> alkyl group optionally substituted with 1 to 3 substituents selected from a fluorine atom and a hydroxyl group, or a C<sub>1-6</sub> alkoxy group optionally substituted with 1 to 3 substituents selected from a fluorine atom, a C<sub>3-8</sub> cycloalkyl group and a 4- to 6-membered heterocycloalkyl group,

R<sub>3</sub> is a hydrogen atom or a C<sub>1-6</sub> alkyl group, and

R<sub>4</sub> is a C<sub>1-6</sub> alkyl group optionally substituted with 1 to 3 substituents selected from a fluorine atom and a hydroxyl group, or a C<sub>1-6</sub> alkoxy group.

3. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 2, wherein R is a methyl group, an ethyl group, a fluoromethyl group or a difluoromethyl group.

4. The compound or a pharmaceutically acceptable acid addition salt thereof according to

claim 3,

wherein R<sub>1</sub> is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, an ethyl group, a 1,1-difluoroethyl group, a methoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, an ethoxy group, a 2-fluoroethoxy group, a 2-propyloxy group, a cyclopropylmethoxy group, a cyclopropyloxy group or an (oxetan-3-yl)oxy group.

5. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 4,

wherein R<sub>2</sub> is a hydrogen atom, a cyano group, a fluorine atom, a chlorine atom, a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, an ethyl group, a methoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, an ethoxy group, a 2-fluoroethoxy group, a 2-propyloxy group, a cyclopropylmethoxy group, a cyclobutylmethoxy group or a (tetrahydro-2H-pyran-4-yl)methoxy group.

6. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 5, wherein R<sub>3</sub> is a hydrogen atom or a methyl group.

7. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 6, wherein R<sub>4</sub> is a methyl group, a fluoromethyl group, a difluoromethyl group, a hydroxymethyl group or a methoxy group.

8. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 2, wherein

R is a methyl group optionally substituted with 1 to 2 fluorine atoms,

R<sub>1</sub> is a hydrogen atom, a chlorine atom, a methyl group optionally substituted with 1 to 3 fluorine atoms, an ethyl group, a C<sub>1-6</sub> alkoxy group optionally substituted with 1 to 3 fluorine atoms, or a C<sub>3-6</sub> cycloalkyloxy group,

R<sub>2</sub> is a cyano group, a chlorine atom, a C<sub>1-6</sub> alkyl group optionally substituted with 1 to 3 fluorine atoms, or a C<sub>1-6</sub> alkoxy group optionally substituted with 1 to 3 fluorine atoms,

R<sub>3</sub> is a hydrogen atom or a methyl group, and

R<sub>4</sub> is a methyl group optionally substituted with 1 to 3 fluorine atoms.

9. A compound selected from the group consisting of the following compounds or a pharmaceutically acceptable acid addition salt thereof:

(R)-3-(4-chloro-3-methoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(R)-1-(2,6-dimethylpyridin-4-yl)-3-(3-methoxy-4-(trifluoromethyl)phenyl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(R)-6-methyl-3-(3-methyl-4-(trifluoromethoxy)phenyl)-1-(2-methylpyridin-4-yl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(R)-3-(4-(difluoromethoxy)-3-methylphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(R)-3-(4-(difluoromethoxy)-3-methylphenyl)-6-methyl-1-(2-methylpyridin-4-yl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(S)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-3-(3-methoxy-4-(trifluoromethoxy)phenyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(S)-6-(fluoromethyl)-3-(3-methoxy-4-(trifluoromethoxy)phenyl)-1-(2-methylpyridin-4-yl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(R)-3-(3-chloro-4-cyclopropoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(R)-3-(4-cyclopropoxy-3-methylphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(R)-3-(3-chloro-4-(difluoromethoxy)phenyl)-6-methyl-1-(2-methylpyridin-4-yl)-5,6,8,9-


tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (S)-3-(4-cyclopropoxy-3-methylphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-  
 5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (R)-3-(3-methoxy-4-(trifluoromethoxy)phenyl)-6-methyl-1-(2-methylpyridin-4-yl)-5,6,8,9-  
 tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (R)-1-(2,6-dimethylpyridin-4-yl)-3-(3-methoxy-4-(trifluoromethoxy)phenyl)-6-methyl-  
 5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (S)-3-(4-(difluoromethoxy)-3-methylphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-  
 5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (S)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-3-(3-methoxy-4-(trifluoromethyl)phenyl)-  
 5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (R)-3-(3-chloro-4-(difluoromethoxy)phenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-  
 tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (R)-3-(3-chloro-4-methoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-  
 tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (R)-3-(3-chloro-4-ethoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-  
 tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (R)-3-(3-chloro-4-isopropoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-  
 tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (S)-3-(3-chloro-4-methoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-5,6,8,9-  
 tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (S)-3-(3-chloro-4-ethoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-5,6,8,9-  
 tetrahydroimidazo[1,5-d][1,4]oxazepine,  
 (S)-3-(3-chloro-4-isopropoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-5,6,8,9-  
 tetrahydroimidazo[1,5-d][1,4]oxazepine,

(R)-3-(3-(fluoromethyl)-4-(trifluoromethoxy)phenyl)-6-methyl-1-(2-methylpyridin-4-yl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine,

(S)-3-(4-(difluoromethoxy)-3-methylphenyl)-6-(fluoromethyl)-1-(2-methylpyridin-4-yl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine, and


(S)-6-(fluoromethyl)-3-(3-methoxy-4-(trifluoromethyl)phenyl)-1-(2-methylpyridin-4-yl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine.

10. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 9, which is (R)-3-(4-chloro-3-methoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

11. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 9, which is (R)-1-(2,6-dimethylpyridin-4-yl)-3-(3-methoxy-4-(trifluoromethyl)phenyl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

12. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 9, which is (R)-3-(3-methoxy-4-(trifluoromethoxy)phenyl)-6-methyl-1-(2-methylpyridin-4-yl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

13. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 9, which is (R)-3-(4-(difluoromethoxy)-3-methylphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

14. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 9, which is (R)-3-(3-chloro-4-(difluoromethoxy)phenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

15 The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 9, which is (S)-3-(4-(difluoromethoxy)-3-methylphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:



or a pharmaceutically acceptable acid addition salt thereof.

16. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 9, which is (S)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-3-(3-methoxy-4-(trifluoromethyl)phenyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

17. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable acid addition salt according to claim 1, and one or more pharmaceutically acceptable excipients.


18. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable acid addition salt according to claim 9, and one or more pharmaceutically acceptable excipients.

19. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 9, which is (R)-3-(3-chloro-4-cyclopropoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

20. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 1, which is (S)-3-(3-chloro-4-(difluoromethoxy)phenyl)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

21. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 1, which is (R)-3-(4-chloro-3-fluorophenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6-,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

22. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 1, which is (R)-3-(3,4-dichlorophenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:




or a pharmaceutically acceptable acid addition salt thereof.

23. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 1, which is (R)-3-(4-chloro-3-(difluoromethyl)phenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:



or a pharmaceutically acceptable acid addition salt thereof.

24. The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 1, which is (S)-3-(3,4-dichlorophenyl)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine represented by the following formula:



or a pharmaceutically acceptable acid addition salt thereof.